Blincyto

B-cell precursor acute lymphoblastic leukemia (ALL) in 1st or 2nd complete remission w/ minimal residual disease (MRD) ≥0.1%; relapsed or refractory B-cell precursor ALL; CD-19 +ve Philadelphia chromosome -ve B-cell precursor ALL in the consolidation phase of multiphase chemotherapy in adult & ped patients ≥1 mth.

MRD +ve B-cell precursor ALL Patient ≥45 kg Induction cycle 1 & consolidation cycles 2-4 (fixed-dose): 28 mcg daily on days 1-28. Allow 14-day treatment-free interval on days 29-42, <45 kg Induction cycle 1 & consolidation cycles 2-4 (BSA-based dose): 15 mcg/m² daily (max: 28 mcg daily) on days 1-28. Allow 14-day treatment-free interval on days 29-42. Premed Adult Prednisone 100 mg IV (or dexamethasone 16 mg) 1 hr prior to 1st dose of each cycle. Ped Dexamethasone 5 mg/m² IV/PO (max: 20 mg) prior to 1st dose in 1st cycle & when restarting infusion after ≥4 hr interruption in 1st cycle. Relapsed or refractory B-cell precursor ALL Patient ≥45 kg Induction cycle 1 (fixed-dose): 9 mcg daily on days 1-7; 28 mcg daily on days 8-28; allow 14-day treatment-free interval on days 29-42. Induction cycle 2 & consolidation cycles 3-5 (fixed dose): 28 mcg daily on days 1-28; allow 14-day treatment-free interval on days 29-42. Continued therapy cycle 6-9 (fixed dose): 28 mcg daily on days 1-28; allow 56-day treatment-free interval on days 29-84, <45 kg Induction cycle 1 (BSA-based dose): 5 mcg/m² daily (max: 9 mcg daily) on days 1-7; 15 mcg/m² daily (max: 28 mcg daily) on days 8-28; allow 14-day treatment-free interval on days 29-42. Induction cycle 2 & consolidation cycles 3-5 (BSA-based dose): 15 mcg/m² daily (max: 28 mcg daily) on days 1-28; allow 14-day treatment-free interval on days 29-42. Continued therapy cycles 6-9 (BSA-based dose): 15 mcg/m² daily (max: 28 mcg daily) on days 1-28; allow 56-day treatment-free interval. Premed Adult Dexamethasone 20 mg IV/PO 1 hr prior to the 1st dose of each cycle, prior to a step dose (eg, cycle 1 day 8) & when restarting infusion after ≥4 hr interruption. Ped Dexamethasone 5 mg/m² IV/PO (max: 20 mg) prior to 1st dose in 1st cycle, step dose (eg, cycle 1 day 8) & when restarting infusion after ≥4 hr interruption in 1st cycle. B-cell precursor ALL in the consolidation phase Patient ≥45 kg 28 mcg daily on days 1-28. Allow 14-day treatment-free interval on days 29-42, <45 kg 15 mcg/m² daily (max: 28 mcg daily) on days 1-28. Allow 14-day treatment-free interval on days 29-42. Premed Adult Dexamethasone 20 mg IV 1 hr prior to 1st dose of each cycle. Ped Dexamethasone 5 mg/m² IV/PO (max: 20 mg) prior to 1st dose in 1st cycle & when restarting infusion after ≥4 hr interruption in 1st cycle.

Hypersensitivity.

Targeted Cancer Therapy

L01FX07 - blinatumomab ; Belongs to the class of other monoclonal antibodies and antibody drug conjugates. Used in the treatment of cancer.

POM